Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Oncology

A Fresh IPO That Long-Term Investors Shouldn’t Ignore

Aktis Oncology, which recently had its IPO, has gained substantial backing from Big Pharma mainstay Eli Lilly. Investors should take note of the biotech firm.

MarketBeat

Upcoming 2026 Medical Events for Healthcare Professionals

Discover the top medical conferences in 2026 for healthcare professionals. Plan your year of learning and networking.

inkl

Inside CTOAM's Precision Oncology Approach and Its Focus on Advanced Diagnostics With Individual Cancer Patients' Needs

At the core of CTOAM's work, Morand explains, is a precision oncology process that integrates multiple diagnostic tools into a single, coordinated pathway. The company supports tumor DNA and RNA sequencing, whole genome liquid biopsies for real-time monitoring, and advanced imaging, including PET-CT scans, depending on what each individual case…

International Business Times

From analysis to the latest developments in health,
read the most diverse news in one place.

Why Wall Street Gave Up on Pfizer—and Why That May Be a Mistake

With activist investors gone and revenue stabilizing, the undervalued pharmaceutical giant offers a compelling chance for value investors in the coming year.

MarketBeat

This Growth Stock With 137% Upside Faces New Challenge: Buy, Hold or Sell?

Not a collapse, just a pivot toward what matters most. Arcus Biosciences still has plenty of potential.

Barchart

Cancer Early Symptoms You Shouldn't Ignore: A Powerful Oncology Awareness Guide

Discover key cancer early symptoms, boost oncology awareness, and learn when to seek medical help to support earlier detection, timely diagnosis, and better treatment outcomes.

Medical Daily

This Oncology Stock Just Hit New All-Time Highs

Revolution Medicines (RVMD) is trading at fresh all-time highs. RVMD exhibits strong technical momentum with a 100% technical “Buy” opinion from Barchart. Shares are up nearly 60% over the past year. Wall Street analysts are overwhelmingly bullish on RVMD, although sentiment is mixed across other platforms. Today’s Featured Stock Valued...

Barchart

Read news from The Economist, FT, and more,
with one subscription

This Undiscovered Biotech Stock Has Quintupled in a Year and Just Hit New Highs

Burning Rock Biotech (BNR) , a precision oncology company from China, has shown exceptional technical momentum and price appreciation. BNR has surged 405% over the past year, hitting a 2-year high on Wednesday. Despite strong technicals, BNR is a highly speculative and risky stock. Today’s Chart of the Day is...

Barchart

Oncology company reports promising cancer find

Shares in Kazia Therapeutics have risen more than 50 per cent after its drug candidate appeared to successfully treat a woman with stage-four breast cancer.

AAP

‘It would be cheaper if I died:’ Cancer patients are battling insurance companies for their lives

IN FOCUS: EXCLUSIVE: Cancer patients, oncologists and advocates tell Rhian Lubin why the US health insurance system needs urgent reform, and is risking the lives of Americans fighting the disease

The Independent UK

Moderna Q3 2025 Earnings Call Transcript

Moderna, Inc (NASDAQ:MRNA) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below. MRNA is building positive momentum. Watch the momentum here This transcript is brought to you by Benzinga APIs. For real-time access to our entire catalog, please visithttps://www.benzinga.com/apis/for a consultation. Operator…

Benzinga

Promising Therapies Extend Survival in Stage 4 Breast Cancer

Stage 4 breast cancer is also known as metastatic breast cancer. As the research evidence reports, it is the most advanced form of the disease.

inkl

1 Growth Stock Under $100 to Buy Before It Soars

This biotech under $100 looks like a growth opportunity worth grabbing before it soars.

Barchart

Kura Oncology Scores $30 Million Boost As New Leukemia Drug Enters Major Trial

Kura Oncology, Inc. (NASDAQ:KURA) shares rose Friday after the biotechnology firm confirmed a $30 million milestone payment from its collaboration with Kyowa Kirin.

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Whitehawk Therapeutics Stock Is Trading Higher Thursday: What's Going On?

Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) shares are rising Thursday after the company announced a multi-year collaboration with Tempus AI Inc (NASDAQ:TEM) to support the development of its oncology pipeline.

Benzinga

Cullinan Therapeutics Cancer Drug Shows Efficacy In Brain Metastases Among Lung Cancer Patients With Certain Mutations

Taiho Oncology Inc. and Cullinan Therapeutics Inc. (NASDAQ:CGEM) shared new data on Sunday from the central nervous system (CNS) involvement cohort of the REZILIENT2 study of zipalertinib for advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations (ex20ins) or uncommon non-ex20ins EGFR mutations.

Benzinga

Moderna Reports Promising Response Rates For Skin Cancer Combo Therapy In Resistant Patients

Moderna Inc. (NASDAQ:MRNA) announced on Sunday that its clinical, safety, and translational data from its Phase 1/2 study evaluating mRNA-4359 in combination with pembrolizumab in patients with checkpoint inhibitor-resistant/refractory (CPI-R/R) melanoma will be presented at the 2025 European Society for Medical Oncology Congress.

Benzinga

Zenas Biopharma Raises $120 Million To Secure Global Rights To Multiple Sclerosis Drug

Zenas BioPharma Inc. (NASDAQ:ZBIO) and InnoCare Pharma Ltd. on Wednesday announced a license agreement granting Zenas global development and commercialization rights to orelabrutinib for multiple sclerosis and across all therapeutic areas other than oncology.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

TransCode Makes Bold Bet On Melanoma Vaccine With Polynoma Buyout

TransCode Therapeutics Inc. (NASDAQ:RNAZ) announced on Wednesday that it has entered a definitive agreement to acquire Polynoma LLC, a privately held biotechnology firm focused on immuno-oncology.

Benzinga

Why Is Cardiff Oncology Stock Trading Lower After Colorectal Cancer Data?

As advancements in cancer treatment continue to evolve, the pursuit of more effective therapies for metastatic colorectal cancer remains a critical focus in the pharmaceutical industry. Cardiff Oncology, Inc. (NASDAQ:CRDF) on Tuesday released data from the ongoing CRDF-004 Phase 2 clinical trial evaluating onvansertib in combination with standard-of-care (SoC) in…

Benzinga

Cardiff Oncology Shares Slide Over 26% In Premarket Trading After Mixed Q2

Following a disappointing second-quarter earnings report, Cardiff Oncology Inc. (NASDAQ:CRDF) experienced a 26.28% drop in its stock value during pre-market trading on Wednesday after reporting mixed Q2 earnings.

Benzinga

AstraZeneca Q2 Sales Beat Estimates On Strong Cancer Drugs Revenues, Reaffirms 2025 Outlook

AstraZeneca Plc (NASDAQ:AZN) on Tuesday reported second-quarter 2025 sales of $14.46 billion, up 12% year over year (+11% at constant currency), marginally beating the consensus of $14.07 billion, driven by double-digit growth in oncology and biopharmaceuticals.

Evening Standard

Cancer drug demand drives higher sales for AstraZeneca

Revenues from oncology products made up 43% of the company’s total sales.

Barchart

Unlocking Oncology’s Future: 3 Trending Cancer Biotech Stocks with ‘Strong Buy’ Ratings

Three emerging biotech companies — Elicio Therapeutics, Cellectis, and Autolus Therapeutics — are attracting “Strong Buy” analyst ratings in 2025 as major clinical, regulatory, and commercial catalysts position them for standout growth in the cancer treatment market.

Evening Standard

Experts call for end to ‘postcode lottery’ in certain cancer services

Health bodies have called for investment in these ‘essential components of cancer care’ so they do not become ‘optional extras’,

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.